Ratings Mankind Pharma Limited

Equities

Market Closed - NSE India S.E. Other stock markets 05:19:42 18/07/2025 pm IST			5-day change	1st Jan Change
2,652.30 ^INR	+0.49%		+4.26%	-7.92%

11/07	Jefferies Adjusts Mankind Pharma's Price Target to INR3,000 From INR2,870, Keeps at Buy	MT
30/06	India's Torrent Pharma to acquire controlling stake in JB Chem and Pharma	RE

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Over the last twelve months, the sales forecast has been frequently revised upwards.
The group usually releases upbeat results with huge surprise rates.

With an expected P/E ratio at 55.57 and 52.24 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The company is not the most generous with respect to shareholders' compensation.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	MANKIND PHARMA LIMITED				1.27TCr
	ELI LILLY AND COMPANY				68TCr
	JOHNSON & JOHNSON				39TCr
	ABBVIE INC.				34TCr
	NOVO NORDISK A/S				29TCr
	ROCHE HOLDING AG				26TCr
	NOVARTIS AG				22TCr
	ASTRAZENECA PLC				21TCr
	MERCK & CO., INC.				20TCr
	AMGEN INC.				16TCr
	Average				27.79TCr
	Weighted average by Cap.